June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
One-year result of intravitreal ranibizumaTo evaluate the therapeutic efficacy of intravitreal ranibizumab injection (IVR) for central retinal vein occlusion (CRVO) using treat-and-extend (TAE) regimen.b injection for central retinal vein occlusion using treat-and-extend regimen
Author Affiliations & Notes
  • Mika Hosogi
    Okayama University Hospital, Okayama city, Japan
  • Yuki Morizane
    Okayama University Hospital, Okayama city, Japan
  • Shuhei Kimura
    Okayama University Hospital, Okayama city, Japan
  • Mio Hosokawa
    Okayama University Hospital, Okayama city, Japan
  • Yusuke Shiode
    Okayama University Hospital, Okayama city, Japan
  • Shinichiro Doi
    Okayama University Hospital, Okayama city, Japan
  • Masayuki Hirano
    Okayama University Hospital, Okayama city, Japan
  • Atsushi Fujiwara
    Okayama University Hospital, Okayama city, Japan
  • Fumio Shiraga
    Okayama University Hospital, Okayama city, Japan
  • Footnotes
    Commercial Relationships Mika Hosogi, None; Yuki Morizane, None; Shuhei Kimura, None; Mio Hosokawa, None; Yusuke Shiode, None; Shinichiro Doi, None; Masayuki Hirano, None; Atsushi Fujiwara, None; Fumio Shiraga, Alcon Japan (C), Alcon Japan (F), AMO Japan (F), Byer (C), Chuo Sangio Co. (F), Novartis Pharma (C), Novartis Pharma (F), Novartis Pharma (F), Pfizer (F), Saanten Pharmaceutical (F), Santen Pharmaceutical (C), SenjuPharmaceutical (F), Topcon Co. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3745. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mika Hosogi, Yuki Morizane, Shuhei Kimura, Mio Hosokawa, Yusuke Shiode, Shinichiro Doi, Masayuki Hirano, Atsushi Fujiwara, Fumio Shiraga; One-year result of intravitreal ranibizumaTo evaluate the therapeutic efficacy of intravitreal ranibizumab injection (IVR) for central retinal vein occlusion (CRVO) using treat-and-extend (TAE) regimen.b injection for central retinal vein occlusion using treat-and-extend regimen. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3745.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the therapeutic efficacy of intravitreal ranibizumab injection (IVR) for central retinal vein occlusion (CRVO) using treat-and-extend (TAE) regimen.

Methods: Twenty eyes of 12 CRVO patients (6 males and 6 females, mean age 70.9 ± 12.2 years) who were treated with IVR using TAE regimen for one year were studied.Monthly injections continued until the central retinal thickness (CRT) decreased to ≤ 300 μm which was determined by optical coherence tomography. When the CRT was ≤ 300 μm, the re-treatment interval was extended by 2 weeks, up to a maximum of 16 weeks. If the CRT was more than 300 μm, this interval was shortened by 1 week. The main outcome measures were 1) changes in best corrected visual acuity (BCVA), CRT, 2) annual number of IVR injection, and 3) the final interval between IVR injections.

Results: The mean BCVA (logarithm of the minimal angle of resolution, log MAR) improved significantly from 0.49 ± 0.39 at baseline to 0.23± 0.33 at 1 year (p = 0.0002, paired t-test). The mean CRT decreased significantly from 558.5 ± 167.3 μm at baseline to 266.3 ± 65.8 μm at 1 year, (p < 0.0001, paired t-test). The mean number of IVR injection was 7.3 ± 2.9 (6 to 12) times in a year, with a mean interval between injections of 10 ± 4.5 weeks.

Conclusions: The use of a TAE regimen for IVR therapy in CRVO was highly effective in improving and maintaining both BCVA and CRT at 1 year. The mean number of IVR injections and the mean interval between them was very variable between cases. Long-term observation and comparisons with pro re nata treatment are needed.<br /> <br />

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×